MiNK Therapeutics develops iNKT cell therapy candidates for cancers and graft versus host disease, still in clinical trials. It last closed at $8.02 on Nov 20, down 6.85% on the day. The next earnings report for INKT is expected around Tue, Mar 30, 2027. For the quarter ended Sep 2026, INKT reported EPS of -$0.50 on revenue of $200,000. Over its last 8 reports the stock moved an average of 5.0% the session after earnings. Over the last 12 months INKT insiders bought $0 of stock on the open market and sold $120K, according to SEC Form 4 filings.
AI Auto Pilots
Is INKT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold INKT.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on INKTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
INKT · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 24% below its 20 day and 35% below its 50 day average. It is 39% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the 52 week low at $7.76, and the nearest resistance the Pivot at $8.13.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.0%/day
Key levels
$16.9352 week high+111.1%
$11.25Swing high (Jul 27)+40.3%
$11.12200 day average+38.7%
$10.99100 day average+37.0%
$10.8050 day average+34.7%
$9.9820 day average+24.4%
$8.49Pivot R1+5.9%
$8.13Pivot+1.4%
$8.02Last close
$7.7652 week low−3.2%
$7.65Pivot S1−4.6%
Indicators
RSI (14)
25.94
Oversold below 30
Oversold
MACD
-0.59
Below its signal line
Bearish
Stochastic
4.5
Near the bottom of its range
Oversold
ADX (14)
19.4
No clear trend
Williams %R
-92.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-194.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−22.5%
Change over 10 sessions
Bearish
ATR (14)
$0.72
Typical daily range, 9.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 20.8%/day
Key levels
$16.9352 week high+111.1%
$11.25Swing high (Jul 27)+40.3%
$11.12200 day average+38.7%
$10.99100 day average+37.0%
$10.8050 day average+34.7%
$9.9820 day average+24.4%
$8.49Pivot R1+5.9%
$8.13Pivot+1.4%
$8.02Last close
$7.7652 week low−3.2%
$7.65Pivot S1−4.6%
Indicators
RSI (14)
34.93
Weak, oversold below 30
Neutral
MACD
-0.56
Below its signal line
Bearish
Stochastic
14.7
Near the bottom of its range
Oversold
ADX (14)
28.5
Trending down
Williams %R
-95.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-248.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−33.2%
Change over 10 sessions
Bearish
ATR (14)
$1.67
Typical daily range, 20.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for INKT
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how INKT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow INKT usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for INKTHow many large options trades hit INKT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in INKT in the last 90 days.
From SEC Form 4 filings by INKT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INKT is in one of them and how their past INKT trades turned out.
MiNK Therapeutics is a biotechnology company based in New York that develops cell therapies built on its iNKT cell platform. Its product candidates are still being tested in clinical trials and have not been approved for sale. The treatments are being studied for conditions such as graft versus host disease, solid tumors and multiple myeloma, and the company's intended customers are patients and the physicians who treat them. It competes with other cell therapy developers and with existing and newer treatments.